STEVEN YU VILLANUEVA, M.D.; MARIA DE MEDINA, M.S.; GUIDO PEREZ, M.D.; K. RAJENDER REDDY, M.D.; LENNOX JEFFERS, M.D.; FREDDIE WATKINS, R.N., M.S.; CARL GOLDSMITH, M.D.; EUGENE R. SCHIFF, M.D.
To the editor: In the June issue, Morrison and colleagues (1) reported on the seroprevalence of antibodies to human immunodeficiency virus (anti-HIV) in patients undergoing hemodialysis. They examined 79 patients and found 3 who tested positive for anti-HIV by enzyme-linked immunoassay (EIA). Two of the three were negative by the Western blot method.
We write to describe our experience with 80 patients on chronic hemodialysis who were screened for anti-HIV first by EIA (Abbott Laboratories, North Chicago, Illinois). Positive samples were confirmed by EIA and Western blot testing at Abbott Laboratories. Samples that showed any reaction to p24 or p41
VILLANUEVA SY, DE MEDINA M, PEREZ G, REDDY KR, JEFFERS L, WATKINS F, et al. Prevalence of Human Immunodeficiency Virus Antibodies and Hepatitis B Markers Among Patients Having Hemodialysis. Ann Intern Med. ;105:967–968. doi: 10.7326/0003-4819-105-6-967_3
Download citation file:
Published: Ann Intern Med. 1986;105(6):967-968.
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use